Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
CA Cancer J Clin ; 70(5): 349-354, 2020 09.
Artigo em Inglês | MEDLINE | ID: mdl-32662880

RESUMO

New York City has been at the epicenter of the coronavirus disease 2019 (COVID-19) pandemic that has already infected over a million people and resulted in more than 70,000 deaths as of early May 2020 in the United States alone. This rapid and enormous influx of patients into the health care system has had profound effects on all aspects of health care, including the care of patients with cancer. In this report, the authors highlight the transformation they underwent within the Division of Hematology and Medical Oncology as they prepared for the COVID-19 crisis in New York City. Under stressful and uncertain conditions, some of the many changes they enacted within their division included developing a regular line of communication among division leaders to ensure the development and implementation of a restructuring strategy, completely reconfiguring the inpatient and outpatient units, rapidly developing the ability to perform telemedicine video visits, and creating new COVID-rule-out and COVID-positive clinics for their patients. These changes allowed them to manage the storm while minimizing the disruption of important continuity of care to their patients with cancer. The authors hope that their experiences will be helpful to other oncology practices about to experience their own individual COVID-19 crises.


Assuntos
COVID-19/epidemiologia , COVID-19/prevenção & controle , Neoplasias Hematológicas/complicações , Hematologia/organização & administração , Oncologia/organização & administração , Serviço Hospitalar de Oncologia/organização & administração , COVID-19/complicações , COVID-19/diagnóstico , Comunicação , Neoplasias Hematológicas/terapia , Hematologia/métodos , Humanos , Oncologia/métodos , Cidade de Nova Iorque/epidemiologia , Ambulatório Hospitalar/organização & administração , Isolamento de Pacientes , SARS-CoV-2 , Telemedicina/organização & administração
2.
J Thromb Thrombolysis ; 49(1): 153-158, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31456167

RESUMO

Primary brain tumors, both benign and malignant, pose a high risk of perioperative venous thromboembolism (VTE) due to the development of a prothrombotic state. Perioperative pharmacologic thromboprophylaxis with subcutaneous (SC) unfractionated heparin (UFH) has significantly reduced VTE associated morbidity. Recent reports suggest an association between prolonged activated partial thromboplastin time (aPTT) due to prophylactic SC UFH and increased bleeding risk. We present three patients with normal baseline coagulation parameters in whom pharmacologic thromboprophylaxis with SC UFH resulted in a marked prolongation of the aPTT, leading to adverse outcomes in two patients. These cases demonstrate the uncertain kinetics of SC UFH and effect on aPTT, suggesting the significance of routine aPTT monitoring in high-risk settings. Given the wide variation in presentations of therapeutic or supratherapeutic values of aPTT in the perioperative neurosurgical setting, we propose a practical standardized approach to the evaluation and management of aPTT prolongation following prophylactic SC UFH administration.


Assuntos
Anticoagulantes/administração & dosagem , Neoplasias Encefálicas , Heparina/administração & dosagem , Procedimentos Neurocirúrgicos/efeitos adversos , Complicações Pós-Operatórias , Trombose Venosa , Idoso , Idoso de 80 Anos ou mais , Anticoagulantes/efeitos adversos , Neoplasias Encefálicas/sangue , Neoplasias Encefálicas/cirurgia , Feminino , Heparina/efeitos adversos , Humanos , Tempo de Tromboplastina Parcial , Complicações Pós-Operatórias/sangue , Complicações Pós-Operatórias/prevenção & controle , Trombose Venosa/sangue , Trombose Venosa/etiologia , Trombose Venosa/prevenção & controle
3.
Arthritis Rheumatol ; 75(10): 1687-1702, 2023 10.
Artigo em Inglês | MEDLINE | ID: mdl-37635643

RESUMO

OBJECTIVE: To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) and EULAR. METHODS: This international multidisciplinary initiative included 4 phases: 1) Phase I, criteria generation by surveys and literature review; 2) Phase II, criteria reduction by modified Delphi and nominal group technique exercises; 3) Phase III, criteria definition, further reduction with the guidance of real-world patient scenarios, and weighting via consensus-based multicriteria decision analysis, and threshold identification; and 4) Phase IV, validation using independent adjudicators' consensus as the gold standard. RESULTS: The 2023 ACR/EULAR APS classification criteria include an entry criterion of at least one positive antiphospholipid antibody (aPL) test within 3 years of identification of an aPL-associated clinical criterion, followed by additive weighted criteria (score range 1-7 points each) clustered into 6 clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular, obstetric, cardiac valve, and hematologic) and 2 laboratory domains (lupus anticoagulant functional coagulation assays, and solid-phase enzyme-linked immunosorbent assays for IgG/IgM anticardiolipin and/or IgG/IgM anti-ß2 -glycoprotein I antibodies). Patients accumulating at least 3 points each from the clinical and laboratory domains are classified as having APS. In the validation cohort, the new APS criteria versus the 2006 revised Sapporo classification criteria had a specificity of 99% versus 86%, and a sensitivity of 84% versus 99%. CONCLUSION: These new ACR/EULAR APS classification criteria were developed using rigorous methodology with multidisciplinary international input. Hierarchically clustered, weighted, and risk-stratified criteria reflect the current thinking about APS, providing high specificity and a strong foundation for future APS research.


Assuntos
Síndrome Antifosfolipídica , Reumatologia , Feminino , Gravidez , Humanos , Estados Unidos , beta 2-Glicoproteína I , Autoanticorpos , Imunoglobulina G , Imunoglobulina M
4.
Blood Coagul Fibrinolysis ; 29(2): 227-230, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29389673

RESUMO

: Due to their ease of use, the direct oral anticoagulants (DOACs) are an attractive treatment option for cancer-associated venous thromboembolism (VTE) and have been readily adopted by many clinicians. A recent published study comparing a DOAC (edoxaban) to the current standard-of-care low molecular weight heparin dalteparin for the treatment of cancer-associated thrombosis showed that edoxaban was noninferior to dalteparin for recurrent VTE, but the risk of major bleeding was higher. We present three patients with high-risk gastrointestinal malignancies complicated by cancer-associated VTE with progression of thrombosis while treated with the oral direct Xa inhibitor rivaroxaban. Upon switching therapy to low molecular weight heparin, we found that these patients had clinical and radiologic improvement of VTE. More studies are needed to evaluate the efficacy of rivaroxaban in high-risk gastrointestinal-VTE. We suggest that in some patients, DOACs may not be sufficient for the treatment of VTEs related to high-risk gastrointestinal malignancies.


Assuntos
Inibidores do Fator Xa/uso terapêutico , Neoplasias Gastrointestinais/complicações , Neoplasias Gastrointestinais/tratamento farmacológico , Rivaroxabana/uso terapêutico , Tromboembolia Venosa/tratamento farmacológico , Idoso , Inibidores do Fator Xa/administração & dosagem , Inibidores do Fator Xa/farmacologia , Feminino , Neoplasias Gastrointestinais/patologia , Heparina de Baixo Peso Molecular/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Rivaroxabana/administração & dosagem , Rivaroxabana/farmacologia
5.
Leuk Lymphoma ; 48(12): 2330-7, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18067007

RESUMO

Multiple myeloma (MM) patients have a propensity for thromboembolic events (TE), and treatment with thalidomide/dexamethasone or lenalidomide/dexamethasone increases this risk. This report describes the use of low-dose aspirin (81 mg) as primary thromboprophylaxis in three series of MM patients receiving thalidomide or lenalidomide with other drugs. In the first regimen (clarithromycin, thalidomide, dexamethasone), initiation of low-dose aspirin negated the occurrence of any further TE. In a second study, prophylactic aspirin given with thalidomide/dexamethasone resulted in a rate of TE similar to that seen with dexamethasone alone (without aspirin). A third study (n = 72) evaluated thrombosis rates with aspirin and a lenalidomide-containing regimen (clarithromycin, lenalidomide, dexamethasone). Of nine occurrences of thromboembolism, five were associated with aspirin interruption or poor compliance. Low-dose aspirin appears to reduce the incidence of thrombosis with these regimens. Routine use of aspirin as antithrombotic prophylaxis in MM patients receiving immunomodulatory drugs with corticosteroids is warranted.


Assuntos
Antineoplásicos/efeitos adversos , Aspirina/uso terapêutico , Mieloma Múltiplo/tratamento farmacológico , Talidomida/análogos & derivados , Talidomida/efeitos adversos , Trombose/prevenção & controle , Adulto , Idoso , Quimioterapia Combinada , Feminino , Heparina de Baixo Peso Molecular/uso terapêutico , Humanos , Lenalidomida , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Talidomida/administração & dosagem
7.
Blood Coagul Fibrinolysis ; 23(8): 751-5, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22964770

RESUMO

To assess the rate and type of maternal and infant complications among pregnant women receiving low-molecular-weight heparin (LMWH). Retrospective study of pregnant women on LMWH referred to two university hematology clinics from January 2001 to December 2010. We recorded the number of pregnancies, indication, dose and dose adjustments for LMWH, pregnancy outcomes (live births, maternal and infant complications) and side effects of LMWH. There were 89 pregnancies in 76 women. The most common indication for LMWH was a history of adverse outcome of pregnancy associated with thrombophilia. LMWH was adjusted in 75 and 45% of pregnancies in women on therapeutic and prophylactic doses, respectively. Live birth rate was 97%. There were 25 maternal and 11 infant complications. Side effects were minimal and included decreased bone mineral density and bleeding. LMWH use among pregnant women is associated with successful pregnancy outcomes. Although side effects were minimal, maternal and infant complications occurred in 28 and 12% of cases, respectively.


Assuntos
Anticoagulantes/uso terapêutico , Heparina de Baixo Peso Molecular/uso terapêutico , Nascido Vivo , Complicações Cardiovasculares na Gravidez/sangue , Tromboembolia/tratamento farmacológico , Trombofilia/tratamento farmacológico , Adulto , Feminino , Humanos , Recém-Nascido , Pessoa de Meia-Idade , Gravidez , Complicações Cardiovasculares na Gravidez/fisiopatologia , Fatores de Risco , Natimorto , Tromboembolia/sangue , Trombofilia/sangue
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa